MacroGenics develops antibody-based cancer therapies using multiple proprietary technology platforms, including bispecific DART molecules and antibody-drug conjugates. Several of its candidates employ novel topoisomerase I inhibitor payloads delivered via ADCs targeting antigens such as B7-H3 and ADAM9 on solid tumors. The company has formed collaborations with major pharmaceutical partners and previously contributed technology to approved biologic products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 13.2 | — | -41 | — |
| Q2 2025 | 22.2 | — | -36.3 | — |
| Q3 2025 | 72.8 | — | 16.8 | — |
| Q4 2025 | 41.2 | — | -14.2 | — |
| Q1 2026 | 20.8 | 57.5% | -36.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PAMT CORP (PAMT), ioneer Ltd (IONR), Richmond Mutual Bancorporation, Inc. (RMBI), Uxin Limited (UXIN), Datavault AI Inc. (DVLT), InterPrivate Investment Partners V, Inc. (IPVV)